Available Cold Sore Tablet Strengths & Treatment Plans
Standard Aciclovir Tablet Strengths
Aciclovir tablets are manufactured in three primary strengths: 200mg, 400mg, and 400mg. The 400mg strength represents the most frequently prescribed option for treating cold sores in adults. Each strength serves specific treatment purposes, with dosing frequency adjusted accordingly. Treatment duration typically ranges from 5-10 days depending on severity and individual response.
Aciclovir 400mg Tablets - Primary Treatment
The 400mg strength offers an optimal balance between effectiveness and dosing convenience. Patients typically take one tablet three times daily for cold sore treatment. This strength may be particularly suitable for first episodes or recurrent outbreaks. EverydayMeds stocks Aciclovir 400mg tablets following appropriate medical assessment and prescription approval.
Alternative Dosage Options
Aciclovir 200mg tablets require more frequent dosing - typically five times daily - which some patients find less convenient. The 400mg strength is generally reserved for severe cases or specific clinical situations as determined by prescribers. Valaciclovir 500mg tablets offer an alternative antiviral option with different dosing schedules, potentially requiring fewer daily doses.
Branded vs Generic Options
Both generic aciclovir and branded versions like Zovirax contain the same active ingredient. Valtrex represents the branded form of valaciclovir. Generic versions typically offer cost savings whilst maintaining equivalent therapeutic effects. EverydayMeds provides both generic and branded options where available, allowing patients and prescribers to choose based on individual preferences and clinical considerations.
Treatment Timing & Effectiveness
Cold sore tablets work most effectively when started at the first sign of symptoms - typically the tingling or burning sensation before blisters appear. Earlier treatment initiation may help reduce outbreak duration and severity. Patients experiencing frequent recurrent episodes might be candidates for suppressive therapy using different dosing regimens as determined by their healthcare provider.
